The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
Open accessAbstract
OBJECTIVE: To characterise whether some selective serotonin reuptake inhibitor (SSRI) antidepressants reduce tamoxifen's effectiveness by inhibiting its bioactivation by cytochrome P450 2D6 (CYP2D6). DESIGN: Population based cohort study. PARTICIPANTS: Women living in Ontario aged 66 years or older treated with tamoxifen for breast cancer between 1993 and 2005 who had overlapping treatment with a single SSRI. MAIN OUTCOME MEASURES: Risk of death from breast cancer after completion of tamoxifen treatment, as a function of the proportion of time on tamoxifen during which each SSRI had been co-prescribed. RESULTS: Of 2430 women treated with tamoxifen and a single SSRI, 374 (15.4%) died of breast cancer during follow-up (mean follow-up 2.38 years, SD 2.59). After adjustment for age, duration of tamoxifen treatment, and other potential confounders, absolute increases of 25%, 50%, and 75% in the proportion of time on tamoxifen with overlapping use of paroxetine (an irreversible inhibitor of CYP2D6) were associated with 24%, 54%, and 91% increases in the risk of death from breast cancer, respectively (P<0.05 for each comparison). By contrast, no such risk was seen with other antidepressants. We estimate that use of paroxetine for 41% of tamoxifen treatment (the median overlap in our sample) would result in one additional breast cancer death within five years of cessation of tamoxifen for every 19.7 (95% confidence interval 12.5 to 46.3) patients so treated; the risk with more extensive overlap would be greater. CONCLUSION: Paroxetine use during tamoxifen treatment is associated with an increased risk of death from breast cancer, supporting the hypothesis that paroxetine can reduce or abolish the benefit of tamoxifen in women with breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Depression and anxiety in women with early breast cancer: five year observational cohort study
Burgess, C., Cornelius, V., Love, S., Graham, J., Richards, M., & Ramirez, A. (2005) · BMJ · doi:10.1136/bmj.38343.670868.d3 · Cited by 1,334
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., Tu, J. V., Henry, D. A., Kopp, A., & Mamdani, M. M. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.082001 · Cited by 766
Self-citationDrug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity
Juurlink, D. N., Mamdani, M., Kopp, A., Laupacis, A., & Redelmeier, D. A. (2003) · JAMA · doi:10.1001/jama.289.13.1652 · Cited by 761
Self-citationLoprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Schneeweiss, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.9.854 · Cited by 711
A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
Cole, M. P., Jones, C. T. A., & Todd, I. D. H. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.33 · Cited by 701
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Major depression after breast cancer: a review of epidemiology and treatment
Fann, J. R., Thomas-Rich, A. M., Katon, W. J., Cowley, D., Pepping, M., McGregor, B. A., & Gralow, J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.10.008 · Cited by 586
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9428-0 · Cited by 552
Anderson, B. O., Yip, C.-H., Smith, R. A., Shyyan, R., Sener, S. F., Eniu, A., Carlson, R. W., Azavedo, E., & Harford, J. (2008) · Cancer · doi:10.1002/cncr.23844 · Cited by 533
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 531
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 469
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., & Brauch, H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2705 · Cited by 467
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Depression, quality of life and breast cancer: a review of the literature
Reich, M., Lesur, A., & Perdrizet-Chevallier, C. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9706-5 · Cited by 442
Day, R., Ganz, P. A., Costantino, J. P., Cronin, W. M., Wickerham, D. L., & Fisher, B. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2659 · Cited by 438
Hemeryck, A., & Belpaire, F. (2002) · Current Drug Metabolism · doi:10.2174/1389200023338017 · Cited by 368
Outpatient gatifloxacin therapy and dysglycemia in older adults.
Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., & Mamdani, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055191 · Cited by 367
Self-citationEll, K., Sanchez, K., Vourlekis, B., Lee, P.-J., Dwight-Johnson, M., Lagomasino, I., Muderspach, L., & Russell, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.041 · Cited by 319
Mamdani, M., Rochon, P., Juurlink, D. N., Anderson, G. M., Kopp, A., Naglie, G., Austin, P. C., & Laupacis, A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.481 · Cited by 281
Self-citationBertelsen, K. M., Venkatakrishnan, K., von Moltke, L. L., Obach, R. S., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.289 · Cited by 276
Drug‐Induced Lithium Toxicity in the Elderly: A Population‐Based Study
Juurlink, D. N., Mamdani, M. M., Kopp, A., Rochon, P. A., Shulman, K. I., & Redelmeier, D. A. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52221.x · Cited by 179
Self-citationJuurlink, D. N., Gomes, T., Lipscombe, L. L., Austin, P. C., Hux, J. E., & Mamdani, M. M. (2009) · BMJ · doi:10.1136/bmj.b2942 · Cited by 170
Self-citationAustin, P. C. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.03.012 · Cited by 145
Self-citationAlfaro, C. L., Lam, Y. W. F., Simpson, J., & Ereshefsky, L. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004000108 · Cited by 142
Tamoxifen, hot flashes and recurrence in breast cancer
Mortimer, J. E., Flatt, S. W., Parker, B. A., Gold, E. B., Wasserman, L. M., Natarajan, L., Pierce, J. P., & For the WHEL Study Group (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9612-x · Cited by 133
Coyne, J. C., Palmer, S. C., Shapiro, P. J., Thompson, R., & DeMichele, A. (2004) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2003.08.012 · Cited by 123
Venkatakrishnan, K., & Obach, R. S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004077 · Cited by 120
Ball, S. E., Ahern, D., Scatina, J., & Kao, J. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00591.x · Cited by 103
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
Rae, J. M., Sikora, M. J., Henry, N. L., Li, L., Kim, S., Oesterreich, S., Skaar, T. C., Nguyen, A., Desta, Z., Storniolo, A. M., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.14 · Cited by 86
Venkatakrishnan, K., Obach, R. S., & Rostami‐Hodjegan, A. (2007) · Xenobiotica · doi:10.1080/00498250701670945 · Cited by 80
Salkeld, E., Ferris, L. E., & Juurlink, D. N. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318166c52e · Cited by 71
Self-citationLash, T. L., Pedersen, L. H., Cronin-Fenton, D. P., Ahern, T. P., Rosenberg, C. L., Lunetta, K. L., Silliman, R. A., Hamilton-Dutoit, S. J., Garne, J. P., Ewertz, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604533 · Cited by 64
Breast cancer recurrence risk in relation to antidepressant use after diagnosis
Chubak, J., Buist, D. S. M., Boudreau, D. M., Rossing, M. A., Lumley, T., & Weiss, N. S. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9828-9 · Cited by 63
Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience
Loprinzi, C. L., Barton, D. L., Sloan, J. A., Novotny, P. J., Dakhil, S. R., Verdirame, J. D., Knutson, W. H., Kelaghan, J. W., & Christensen, B. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181679150 · Cited by 61
Antidepressants, Warfarin, and the Risk of Hemorrhage
Kurdyak, P. A., Juurlink, D. N., Kopp, A., Herrmann, N., & Mamdani, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000186869.67418.bc · Cited by 54
Self-citationAhern, T. P., Pedersen, L. H., Cronin-Fenton, D. P., Sørensen, H. T., & Lash, T. L. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0516 · Cited by 52
Effect of Venlafaxine versus Fluoxetine on Metabolism of Dextromethorphan, a CYP2D6 Probe
Amchin, J., Ereshefsky, L., Zarycranski, W., Taylor, K. P., Albano, D., & Klockowski, P. M. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010159 · Cited by 48
Lack of Attenuation in the Antitumor Effect of Tamoxifen by Chronic CYP Isoform Inhibition
Lehmann, D. F., Nelsen, J. L., Ramanath, V. S., Newman, N. B., Duggan, D. B., & Smith, A. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004266618 · Cited by 29
Cited by
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Drug combination therapy increases successful drug repositioning
Sun, W., Sanderson, P. E., & Zheng, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.015 · Cited by 436
Basic Review of the Cytochrome P450 System
McDonnell, P., & Dang, P. (2013) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2013.4.4.7 · Cited by 307
Metadata
- Authors
- Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2010-02-08
- Volume
- 340
- Issue
- feb08 1
- Pages
- c693-c693
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1997530992
- Cited by
- 466
- References
- 47
- FWCI
- 61.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.